Drug Candidate, CQ-001 (cannabidiol “CBD” + IP system), also demonstrated considerably diminished seizures at better doses, with fewer CBD, in comparison to typical CBD.
TORONTO, ON / ACCESSWIRE / December 8, 2022 / CANAQUEST Clinical CORP (OTC PINK:CANQF) (the “Company” or “CanaQuest“), a scientific-phase daily life sciences company focused on drug discovery and progress of subsequent-technology focused cannabinoid therapeutics for the central nervous program (CNS), these days declared Statistically Considerable efficacy outcomes from the Clinical Dose & Efficacy Research (“Analyze”) done by Dr. W McIntyre Burnham, emeritus professor of the University of Toronto’s Temerty School of Medicine. In comparison to typical CBD, CQ-001 (cannabidiol “CBD” + IP components – important fatty acids) demonstrated 40{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} more seizure reduction at a medium dose in the maximal electroshock seizure (MES) model. This outcome indicates that CQ-001 is stronger than regular CBD, and could be made use of a reduced dose to achieve seizure control.
Highlights derived from the Examine are as follows:
-
The improved efficacy from these medical experiments further more validates the pre-medical demo final results obtained by Dr. Steven Laviolette, a professor and neuroscientist, at Western University.
-
These benefits established the phase for substantially more compact dosages of CBD building the wished-for outcomes without the need of the negative facet outcomes and will define a dosage of CQ-001 for a clinical trial (Phase II/III, double-blind demo, 60 individuals).
-
CanaQuest has recognized the regulatory pathways to obtain Rx Drug Identification Numbers (DINs) in Canada and the Usa for Epilepsy scarce neurological conditions. CQ-001, in mixture with its proprietary processing and delivery technique, is believed to be accredited in about 3 a long time.
“More testing will be needed, however preliminary tests recommend that CQ-001 is stronger than regular CBD,” claimed Burnham, pharmacologist and co-director of EpLink.
Paul Ramsay, President, mentioned, “The Medical Review success reconfirm the pre-medical demo success done at Western University, and more substantiate the magnitude of this daily life-transforming discovery.”
Physicians, psychiatrists, pharmacists, and healthcare practitioners fascinated in joining our increasing network can speak to [email protected].
About: The Ontario Brain Institute – EpLink
The Ontario Brain Institute is a provincially funded, not-for-profit business that accelerates discovery and innovation, benefiting the two clients and the economy. https://braininstitute.ca/about-obi
EpLink is the Epilepsy Study Method of the Ontario Mind Institute and is targeted on getting new approaches to diagnose, handle and increase the lives of men and women residing with drug-resistant epilepsy. The program is funded by the Ontario Mind Institute and aims to carry health innovations directly to the epilepsy local community. https://eplink.ca/
About: CanaQuest Health-related Corp
CanaQuest Medical, a scientific-phase, lifestyle sciences enterprise, is targeted on the drug discovery and growth of subsequent-era qualified therapeutics within just the endocannabinoid method and particular mind receptors. The Enterprise is targeted on managing neurological situations, this kind of as epilepsy, nervousness, melancholy, and Put up Traumatic Tension Problem “PTSD”, which includes habit.The Corporation is the sector husband or wife for research and product or service enhancement with Dr. Steven Laviolette, a professor, and neuroscientist, with a long time of working experience in the subject of mental wellbeing and cannabinoids, at Western College. Dr. Laviolette and his group of 13 researchers created two remarkable discoveries that are drug candidates targeting neurological conditions: Drug applicant,CQ-001, supported by (cannabidiol “CBD” + IP system) – molecules bond and synergistically attach to PPAR receptors letting CQ-001 to cross the blood-brain barrier (BBB) to goal the central anxious system (the brain) with amplified effects and efficacy. CBD by by itself did not do this in the pre-clinical trial analysis. The next Drug candidate, CQ-002, supported by (cannabinoid “THC” + IP formula), is a safer option to all other THC products and solutions based on pre-clinical trial success. An OTC (significantly less potent variation) of CQ-001, branded as Mentanine®, targeting stress and anxiety, melancholy, and PTSD (without having statements), is obtainable for sale by means of www.canaqueststore.com in the US.
Acknowledgement:
CanaQuest has been named: 2022 Worldwide Excellence Awards
Most effective Healthcare Hashish and Botanical Oils Product or service Growth Business, 2022 North America
– awarded by Global Wellbeing & Pharma, Uk. https://www.ghp-news.com/about-us/
CANAQUEST Call:
Paul Ramsay, President
CanaQuest Health care Corp
[email protected]
Tel: 416.704.3040
www.canaquest.com
www.canaqueststore.com
Supply: CanaQuest Health-related Corp.
Look at resource version on accesswire.com:
https://www.accesswire.com/730917/CanaQuest-Achieves-Statistically-Substantial-Reduction-of-Seizures-for-Epilepsy-In comparison-to-Conventional-CBD
